NanoViricides Seeks FDA Orphan Drug Designation for Measles Therapy
NanoViricides has submitted a request to the FDA for orphan drug designation for its measles therapeutic candidate. Orphan status may grant seven-year U.S. market exclusivity, tax credits, and fee waivers, potentially reducing development costs and enhancing the therapy’s commercial value.
1. FDA Filing Details
NanoViricides has filed an application with the U.S. Food and Drug Administration seeking orphan drug designation for its lead measles therapeutic candidate to target an area with no approved antiviral treatments.
2. Orphan Status Incentives
Orphan designation in the U.S. grants seven-year market exclusivity for the indication, eligibility for up to 25% clinical trial tax credits and waiver of certain FDA fees, lowering financial barriers to development.
3. Market and Next Steps
The FDA typically reviews orphan drug applications within 90 days; a positive decision would allow NanoViricides to advance into pivotal clinical trials and position its measles treatment for commercialization in a largely untapped market.